Immucor Accepts $2 Billion Private Equity Buyout, But Open To Richer Offer
This article was originally published in The Gray Sheet
Executive Summary
Blood transfusion testing product maker Immucor will gain added financial resources for future growth following investment firm TPG Capital’s purchase of the company for $1.97 billion, the firm announced July 5.